Zentalis Pharmaceuticals (ZNTL) Interest Coverage Ratio (2019 - 2026)
Zentalis Pharmaceuticals (ZNTL) posted quarterly Interest Coverage Ratio of 0.73 for Q1 2026, up 5.53% year-over-year from 0.69 in Q1 2025, and up 99.98% quarter-over-quarter from 3399.36 in Q4 2025.
Zentalis Pharmaceuticals (ZNTL) Interest Coverage Ratio (2019 - 2026) Analysis & Trends
Zentalis Pharmaceuticals' Interest Coverage Ratio history runs 8 years deep, the most recent figure standing at 0.73 for Q1 2026.
- In Q1 2026, Interest Coverage Ratio rose 5.53% year-over-year to 0.73; the TTM figure through Mar 2026 stood at 2.81 (up 22.13% YoY), while the FY2025 annual figure was 22.47, down 2803.38% from the prior year.
- Interest Coverage Ratio for Q1 2026 stood at 0.73, up from 3399.36 in the prior quarter.
- The five-year high for Interest Coverage Ratio was 0.37 in Q1 2024, with the low at 3399.36 in Q4 2025.
- The 5-year median for Interest Coverage Ratio is 1.88 (2023), against an average of 215.61.
- The sharpest annual moves came in 2022 and 2025: Interest Coverage Ratio soared 98.95% in 2022, then slumped 44225.59% in 2025.
- Zentalis Pharmaceuticals' Interest Coverage Ratio stood at 0.73 in 2022, then sank by 1354.03% to 10.61 in 2023, then grew by 27.74% to 7.67 in 2024, then plunged by 44225.59% to 3399.36 in 2025, then jumped by 99.98% to 0.73 in 2026.
- Business Quant data shows ZNTL's Interest Coverage Ratio at 0.73 in Q1 2026, 3399.36 in Q4 2025, and 2.27 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Zentalis Pharmaceuticals | 255.14 Mn | 255.14 Mn | - | -0.89 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.89 |
| Mar 31, 2026 | -0.73 |
| Dec 31, 2025 | -3,399.36 |
| Sep 30, 2025 | -2.27 |
| Jun 30, 2025 | -0.63 |
| Mar 31, 2025 | -0.78 |
| Dec 31, 2024 | -7.67 |
| Sep 30, 2024 | -2.76 |
| Jun 30, 2024 | -1.02 |
| Mar 31, 2024 | -0.37 |
| Dec 31, 2023 | -10.61 |
| Sep 30, 2023 | -0.92 |
| Jun 30, 2023 | -1.48 |
| Mar 31, 2023 | -2.63 |
| Sep 30, 2022 | -0.73 |
| Jun 30, 2022 | -9.33 |
| Mar 31, 2022 | -8.51 |
| Sep 30, 2021 | -69.24 |
| Jun 30, 2021 | -47.08 |
| Mar 31, 2021 | -30.62 |